According to the Zhitong Finance App, Kyodo Pharmaceutical (300966.SZ) released its report for the third quarter of 2026. In the first three quarters, the company achieved revenue of 515 million yuan, an increase of 13.08% over the previous year. Net loss attributable to shareholders of listed companies was 487.71 million yuan. Net loss attributable to shareholders of listed companies was $48.2596 million after deducting non-recurring profit and loss.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.